OSR Holdings Appoints Scientific Co-Founder Dr. Andreas Niethammer as Chief Executive Officer of Vaximm AG to Lead Next Phase of Immuno-Oncology Expansion

Core Insights - OSR Holdings, Inc. has appointed Dr. Andreas Niethammer as the new CEO of Vaximm AG, effective December 1, 2025, marking a significant leadership change in the company [1][4] - Dr. Niethammer is recognized for his expertise in oncology and has been instrumental in developing Vaximm's oral T-cell immunotherapy platform, particularly the lead candidate VXM01 targeting VEGFR-2 [2][5] - The company plans to integrate its anti-angiogenic immune activation platform with viral oncolysis technologies to enhance its immuno-oncology offerings, with a strategic collaboration expected to be announced soon [3][4] Company Overview - Vaximm AG is a Swiss-German biotechnology company focused on oral T-cell vaccination, utilizing live, attenuated bacterial vectors to induce immune responses against tumors [5] - The lead therapeutic candidate, VXM01, has shown clinical activity and safety across multiple cancer types, particularly in pancreatic cancer and glioblastoma [2][5] - OSR Holdings, Inc. is a global healthcare holding company that supports biomedical innovations across various sectors, including immuno-oncology and regenerative biologics [6]